<?xml version="1.0" encoding="UTF-8"?>
<ref id="ppat.1007395.ref041">
 <label>41</label>
 <mixed-citation publication-type="journal">
  <name>
   <surname>Jacobson</surname>
   <given-names>JM</given-names>
  </name>, 
  <name>
   <surname>Thompson</surname>
   <given-names>M a</given-names>
  </name>, 
  <name>
   <surname>Lalezari</surname>
   <given-names>JP</given-names>
  </name>, 
  <name>
   <surname>Saag</surname>
   <given-names>MS</given-names>
  </name>, 
  <name>
   <surname>Zingman</surname>
   <given-names>BS</given-names>
  </name>, 
  <name>
   <surname>D’Ambrosio</surname>
   <given-names>P</given-names>
  </name>, 
  <etal>et al</etal>
  <article-title>Anti-HIV-1 activity of weekly or biweekly treatment with subcutaneous PRO 140, a CCR5 monoclonal antibody</article-title>. 
  <source>J Infect Dis</source>. 
  <year>2010</year>;
  <volume>201</volume>: 
  <fpage>1481</fpage>–
  <lpage>7</lpage>. 
  <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1086/652190" xmlns:xlink="http://www.w3.org/1999/xlink">10.1086/652190</ext-link>
  <?supplied-pmid 20377413?>
  <pub-id pub-id-type="pmid">20377413</pub-id>
 </mixed-citation>
</ref>
